The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML

Burnett, Alan Kenneth, Russell, Nigel H., Culligan, Dominic, Cavanagh, Jamie, Kell, Jonathan, Wheatley, Keith, Virchis, Andra, Hills, Robert Kerrin ORCID: https://orcid.org/0000-0003-0166-0062 and Milligan, Donald 2012. The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML. British Journal of Haematology 158 (4) , pp. 519-522. 10.1111/j.1365-2141.2012.09165.x

Full text not available from this repository.

Abstract

The AML16 trial evaluated the combination of the farnesyltransferase inhibitor, tipifarnib, and low dose cytarabine (LDAC) in older acute myeloid leukaemia (AML) patients in a ‘Pick a Winner’ design. The aim was to double remission rates compared to LDAC, with initial evaluation after 100 patients. Failure to improve remission would result in discontinuation. A total of 65 patients, median age 74 years (range 62–86), were randomized. After reviewing the first 45 patients, the Data Monitoring Committee concluded that the overall aspirations would not be met and recommended closure. The addition of tipifarnib had no effect on response, toxicity or survival.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General) R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Uncontrolled Keywords:	AML; elderly; chemotherapy; clinical trial
Publisher:	Wiley-Blackwell
ISSN:	0007-1048
Last Modified:	24 Oct 2022 09:57
URI:	https://orca.cardiff.ac.uk/id/eprint/42680

Citation Data

Cited 45 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item